Paul Hatala, Ph.D.
VP, Chemical Development and CMC
Paul Hatala is vice president of Chemical Development and Chemistry, Manufacturing and Controls (CMC) at Stoke Therapeutics. Paul oversees all chemical development and CMC activities. Paul is an expert in oligonucleotides and has extensive experience developing novel technologies, implementing technology transfers, and development of medicines from early clinical phases through product registration. He has a deep understanding of drug mechanisms of action, biologics, and therapeutic areas including rare diseases, oncology, and cardiology.
Prior to Stoke, Paul was an independent consultant for biotech and pharmaceutical companies specializing in the development of complex molecular entities. He holds a B.S. in chemistry from the University of Denver and a Ph.D. in organic chemistry from Syracuse University.